Earnings History Data for Outlook Therapeutics, Inc. (OTLK) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Outlook Therapeutics, Inc.
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14-02-2024 | PM | OTLK | Outlook Therapeutics, Inc. | 107.77 | -0.04 | -0.05 | -0.08 | Outlook Therapeutics GAAP EPS of -$0.04 beats by $0.01 [2/14/2024 8:12 AM] |
0.4157 | 0.02 (3.92%) |
0.43 | 0.03 (8.25%) |
0.20 - 2.03 | 1,072,673 | 1,490,000 | 32,430 | ||
| 22-12-2023 | PM | OTLK | Oncobiologics | 109.00 | -0.05 | -0.05 | 0.00 | Outlook Therapeutics GAAP EPS of -$0.24 [12/22/2023 11:45 AM] |
0.4181 | -0.01 (-2.29%) |
0.44 | 0.01 (2.13%) |
0.20 - 2.03 | 1,089,121 | 1,390,000 | 28,125 | ||
| 14-08-2023 | PM | OTLK | Oncobiologics | 413.00 | -0.08 | -0.04 | 0.00 | Outlook Therapeutics GAAP EPS of -$0.08 [8/14/2023 11:15 AM] |
1.56 | -0.04 (-2.50%) |
1.58 | -0.02 (-1.25%) |
0.80 - 2.03 | 2,198,441 | 900,000 | 15,706 | ||
| 14-02-2023 | PM | 9:05 AM ET (Feb 14) |
OTLK | Outlook Therapeutics, Inc. | 328.53 | -0.08 | -0.04 | -0.08 | Outlook Therapeutics GAAP EPS of -$0.08 [2/14/2023 8:30 AM] |
1.20 | 0.0 (0.00%) |
1.20 | 0.0 (0.00%) |
0.68 - 2.12 | 412,731 | 600,000 | 1,739 | |
| 29-12-2022 | PM | OTLK | Outlook Therapeutics, Inc. | 241.97 | N/A | -0.07 | -0.08 | Outlook Therapeutics GAAP EPS of -$0.31 in-line [12/29/2022 9:45 AM] |
1.08 | 0.07 (6.93%) |
1.04 | 0.03 (2.97%) |
0.68 - 2.12 | 800,688 | 640,000 | 12,885 | ||
| 10-08-2022 | PM | 8:05 AM ET (Aug 10) |
OTLK | Oncobiologics | 276.00 | -0.08 | -0.08 | 0.00 | Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01 [8/10/2022 8:20 AM] |
1.23 | 0.04 (3.36%) |
1.17 | -0.02 (-1.68%) |
0.68 - 2.87 | 202,278 | 510,000 | 4,906 | |
| 14-02-2022 | PM | OTLK | Oncobiologics | 309.00 | -0.08 | -0.07 | 0.00 | Outlook Therapeutics GAAP EPS of -$0.08 [2/14/2022 8:12 AM] |
1.33 | -0.02 (-1.48%) |
1.34 | -0.01 (-0.74%) |
1.19 - 3.27 | 544,070 | 970,000 | 920 | ||
| 14-05-2021 | PM | OTLK | Oncobiologics, Inc. | 344.00 | -0.09 | -0.11 | 0.00 | Outlook Therapeutics EPS misses by $0.01 [5/14/2021 8:47 AM] |
2.10 | 0.16 (8.25%) |
2.06 | 0.12 (6.16%) |
0.58 - 4.26 | 726,590 | 820,000 | 9,582 | ||
| 24-12-2020 | ?? | 8:05 AM ET (Dec 23) |
OTLK | Outlook Therapeutics, Inc. | 186.96 | N/A | -0.10 | -0.24 | Outlook Therapeutics EPS beats by $0.01 [12/23/2020 9:15 AM] |
1.55 | -0.03 (-1.90%) |
1.44 | -0.11 (-7.10%) |
0.50 - 1.73 | 933,574 | 873,319 | 500 | |